Krystal Biotech, Inc.
KRYS
Clasificación en acciones
#2176
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on... Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.
Precio por acción
$317.87
Última sincronización: 2026-10-16
Capitalización bursátil
$9.41B
Cambio (1 día)
-3.68%
Cambio (1 año)
67.10%
País
US
Comercio Krystal Biotech, Inc. (KRYS)
Categoría
Healthcare
EPS de Krystal Biotech, Inc. (KRYS)
EPS a fecha de June 2026 TTM: $8.27
Según los últimos informes financieros y el precio de las acciones de Krystal Biotech, Inc., el EPS actual de la empresa (TTM) es $8.27. Al final del año 2023, la empresa tenía un EPS de $0.40 un aumento con respecto a al EPS de 2022, que fue de $-5.49.
Historial de EPS de Krystal Biotech, Inc. desde 2016 hasta 2026
EPS al final de cada año
| Año | EPS | Cambiar |
|---|---|---|
| 2026 (TTM) | $8.27 | 165.06% |
| 2024 | $3.12 | 680.00% |
| 2023 | $0.40 | -107.29% |
| 2022 | $-5.49 | 75.40% |
| 2021 | $-3.13 | 83.04% |
| 2020 | $-1.71 | 42.50% |
| 2019 | $-1.20 | 23.71% |
| 2018 | $-0.97 | -34.46% |
| 2017 | $-1.48 | 448.15% |
| 2016 | $-0.27 | 0.00% |
EPS de empresas similares o competidoras
| Empresa | EPS | Diferencia de EPS | País |
|---|---|---|---|
| $17.32 | 109.43% |
US
|
|
| $-7.98 | -196.49% |
US
|
|
| $-5.29 | -163.97% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | 235.43% |
NL
|
